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ANI Pharmaceticals 
ANIP / NASDAQ 
 
Initiating Coverage      Investment Rating: Sell 
 
 
PRICE: USD 78.48 S&P 500: 3,066.91 DIJA: 27,347.36 RUSSELL 2000: 1,589.33 
• In September 2019, ANI launched Vancomycin Hydrochloride for Oral Solution, which is a prescription 
medication administered orally for treatment of enterocolitis, and In October 2019, ANI launched Aspirin 
and Extended Release Dipyridamole capsules  
• In June 2019, ANI launched Ranitidine, and got approval for the commercialization of Vancocin oral 
solution. 
• On August 6, 2018, ANI’s subsidiary, ANI Canada, acquired all the issued and outstanding equity interests 
of WellSpring, a Canadian company that performs contract development and manufacturing of 
pharmaceutical products 
• During 2018, ANI launched 11 products. 
 
Valuation 2019 A 2020 E 2021 E 
EPS 5.29 4.79 5.51 
P/E 13.78 14.2 13.7 
P/CFPS 14.52 10.86 10.56 
P/BVPS 3.41 2.74 2.486 
EV/EBITDA 10.62 9.8 9.5 
 
Market and Trading Information  
Equity Market Cap (USD): 949.38 Million 52-Week Range (USD): 36.92 - 86.96 
Enterprise Value (USD): 1.09 Billion 12-Month Stock Return: 50.56% 
Shares Outstanding (M): 12.09  Dividend / Capital Gain Yields: 0% / 50.56% 
Estimated Float (M): 9.22 12-Month Russell 2000 Return: 4.37% 
3-mo Avg. Daily Volume (K): 604.3 Beta: 1.96 
 
Company Quick View: 
Location:  210 Main Street West,Baudette, MN 56623 United States 
 
Industry:  Pharmaceutical preparations (SIC 2834)/ Pharmaceutical Preparation Manufacturing       
(NAICS 325412) 
 
Description:  ANI Pharmaceuticals is a pharmaceutical company focused on developing, 
manufacturing, and marketing branded and generic prescription pharmaceuticals. The company has 
over 40 products and produces liquid, powder and oral solid dose products, including those 
requiring containment. ANI's line of Rx products is sold to the U.S's largest wholesalers and 
distributors, smaller regional distributors and chains, as well as the top pharmacy and retail outlets in the country  
 
Key Products & Services:  Its areas of product development include narcotics, oncolytic, hormones and steroids, 
and complex formulations involving extended release and combination products. 
 
Website: http://www.anipharmaceuticals.com.  
 
Analyst: Gbolahan Olaoluwa  
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STOCK PRICE PERFORMANCE 
 
Source: Yahoo Finance 
Figure 1: 5-year Stock Price Performance 
ANI Pharmaceuticals (ANIP) closed on the NASDAQ at USD 78.48 on November 1, 2019. 
Within the five year period (12/1/2014 – 11/1/2019) shown in Figure 1 above, ANI’s stock has 
risen from USD 53.29 to the current USD 78.48. Its stock dropped to USD 29.01 in February 
2016 because of Martin Shkreli and Valeant's (VRX) troubles that affected all specialty 
pharmaceuticals’ shares. The current total year to date return (YTD) for ANI Pharmaceuticals’ 
stock is 74.32 percent, which is much greater than its competitor, Amphastar Pharmaceuticals 
(AMPH), which had a YTD return of -1.71 percent. ANI’s annualized return was 89.24 percent 
and that of its competitor was -2.05 percent. For the five year period shown in the graph above, 
while Russell 2000 had a total return of 45.57 percent, and an average annual return of 7.81 
percent, ANI had a total return of 90.49 percent, and an average annual return of 13.77 percent. 
In other words, ANI has shown better performance than both its competitor and the market. 
Amphastar’s poor stock price performance might be as a result of its inability to generate 
incremental cash flows, even with its new product approvals earlier in 2019.  
 
INVESTMENT DECISION SUMMARY 
I project the intrinsic value for ANI Pharmaceuticals Inc.’s stock to be USD 61.59 per share, 
using a corporate valuation model that discounts free cash flows at the average cost of funding 
(WACC). The outcome of my analysis shows that ANI’s stock is currently overvalued. The price 
per share that I estimate is lower than its current market value at November 1, 2019 of USD 
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COMPANY DESCRIPTION 
ANI Pharmaceuticals Inc. is a company that was founded and incorporated on August 29, 1996 
under the laws of the Province of Ontario as Structured Biologicals Inc. It was reincorporated in 
Delaware on June 26, 2001 as Ben-Abraham Technologies Inc. and the name later changed to 
BioSante Pharmaceuticals, Inc. in Nov. 1999. The company adopted its present name on July 18, 
2013. Its consolidated subsidiaries are ANIP Acquisition Company and ANI Pharmaceuticals 
Canada Inc. The company has three pharmaceutical manufacturing facilities of which two are 
located in Baudette, Minnesota and one is located in Oakville, Ontario, Canada. The corporate 
headquarter is located at 210 Main Street West, Baudette, MN 5662. 
ANI Pharmaceuticals acquired ANIP Acquisition Company (ANIP) on June 19, 2013. ANI also 
acquired 31 previously marketed generic drug products from Teva Pharmaceuticals on Dec. 26, 
2013. On July 1, 2014, ANI acquired the drug product Lithobid®. Other acquisitions include rights 
to manufacture promote, distribute and sell (1) the drug product Vancocin® (Aug. 1, 2014); (2) 
Abbreviated Drug Applications for 23 generic products (2015); (3) Abbreviated New Drug 
Application (ANDAs) for 23 previously marketed generic drug products from IDT Australia, Ltd 
(Apr. 4, 2018); (4) acquired a portfolio of six generic products, related manufacturing and supply 
agreements, and equipment and technical know-how from Amneal Pharmaceuticals, LLC and 
Impax Laboratories, Inc. (May 7, 2018); (5) acquired all the issued and outstanding equity interests 
of WellSpring Pharma Services Inc. (Aug. 6, 2018). 
ANI Pharmaceuticals develops, manufactures, and markets both branded and generic prescription 
pharmaceuticals. The company also produces liquid, powder and oral solid dose products, 
including those requiring containment and it does contract production for other companies. The 
company has over 40 products including controlled substances, oncolytic, hormones and steroids, 
etc. ANI Pharmaceuticals operates under the industry with SIC 2834 (Pharmaceutical Preparations, 
Medical). It belongs to the Biomedical, Index S&P 600, Russell 2000, and Russell 3000. Its target 
customers are pharmacies and hospitals. 
ANI Pharmaceuticals focuses on niche and high barrier to entry opportunities to increase demand 
and acquire more market share. They are constantly researching and producing high quality 
products and gaining more patents for their product. The company has 77 products currently in the 
development stage. Its strong capital position and experienced management team are a plus to the 
company because it increases investors’ confidence. 
ANI Pharmaceuticals have about 25 competitors including Amphastar Pharmaceuticals, Alexion 
Pharmaceuticals, Vertex Pharmaceuticals, Amneal Pharmaceuticals, and other pharmaceuticals 
and laboratories that deal in generic medication. ANI Pharmaceuticals Inc., with its net profit 
margin of 12.11%, ranks No. 34 in Major Pharmaceutical Preparations industry and ranks No. 83 
in Healthcare sector, in the area of profitability in 2018. 
 
MANAGEMENT AND CORPORATE GOVERNANCE 
ROBERT E. BROWN, JR., has been Chairman and a Director of ANI Pharmaceuticals, Inc. 
since June 19, 2013. He is 68 years old and has equities valued at USD 799,915 (ANI 
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pharmaceuticals). His total compensation from ANI Pharmaceuticals has increased from USD 
121,750/year in 2014 to USD 273,573/year in 2018. He is the founder of Meridian Venture 
Partners LLC (1987). He is also on the board of Planalytics, Inc. and Managing Partner at 
Meridian Venture Partners II LP. He once held the position of President and Director at Miami 
Valley Portfolio Management, Inc. Mr. Brown received an undergraduate degree from Princeton 
University, an MBA from The Wharton School of the University of Pennsylvania and a graduate 
degree from The University of Pennsylvania Law School. 
 
ARTHUR S. PRZYBYL, is the President and Chief Executive Officer. He is 62 years old and 
receives compensation of USD 4,197,933 (USD 3,580,292 in 2017 and USD 2,514,063 in 2018). 
According to Mergent Online, his compensation is about two times the compensation for this 
position in the industry. Mr. Przybyl joined ANI in March 2009 as President and CEO. He was 
previously the President and CEO of Akorn, Inc., a NASDAQ specialty pharmaceutical 
company. He was also President of Hearing Innovations, Inc. and the President and COO of 
Bioject, Inc. He has also held several sales and marketing management positions for specialty 
pharmaceutical companies.  
STEPHEN P. CAREY, is the Vice President and Chief Financial Officer (since May 6, 2016). 
He is in charge of the company’s finance, accounting and information technology functions. His 
total compensation is USD 1,438,750, which includes salary, stock awards, options awards, non-
equity incentives, and other compensation. Mr. Carey has over 20 years of experience as a 
financial executive, 15 of which are in the pharmaceutical industry. Between June 2007 and 
October 2015, he held various positions including Senior Vice President, Controller and 
Principal Accounting Officer in ANI pharmaceuticals. Mr. Carey graduated from Montclair State 
University with a B.S. in Accounting and began his career at PriceWaterhouseCoopers, after 
which he held various financial and accounting positions at Schering Plough Corporation (now 
Merck & Co.). Mr. Carey is a CPA (inactive). 
 
JAMES G. MARKEN, Sr. is the Vice President, Operations and Product Development. His total 
compensation is USD 1,009,589. He is the head for the production, engineering and logistics 
functions for the ANI Pharmaceuticals multi-site prescription drug, and potent compound 
facilities in Baudette, Minnesota. Mr. Marken got his B.S. degree in Chemistry from Bemidji 
State University. He joined the company in 2007 as the general manager of the Minnesota 
facilities. He previously worked at Solvay Pharmaceuticals and has over 20 years of 
pharmaceutical industry experience. 
  
DR. DAVID SULLIVAN is the Vice President, Quality Operations since February 3, 2015. Dr. 
Sullivan joined ANI in April 2014. He earned his Ph.D. in Analytical Chemistry and his B.S. in 
Chemistry from South Dakota State University. He worked in quality operations for 
pharmaceutical firms, including Abbvie and then spent 9 years at Boston scientific where he was 
responsible for cGMP laboratories, quality engineering, and systems before joining ANI. 
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ROBERT SCHREPFER, Sr. Vice President, Business Development and Specialty Sales (since 
August 12, 2013). His duties include identifying and advancing ANI's product pipeline and 
contract manufacturing opportunities. His total compensation is USD 1,444,156. He served as a 
Director of ANI from June 19, 2013 until July 12, 2013. Mr. Schrepfer was Vice President at 
Bear Stearns & Cos, Inc. and Managing Director and Assistant Portfolio Manager at Healthcare 
Value Capital in 2005. Mr. Schrepfer is a Member of the Health Sector Advisory Council at 
Duke University where he earned his MBA in Finance and Health Sector Management.  
 
DR. MARK J. GINSKI is the Vice President, Corticotropin Product Development. He is an 
experienced pharmaceutical executive with almost 20 years of experience in the development of 
small molecules, peptides and biologics. He joined ANI in May 2016. Previously, he worked at 
Mallinckrodt Pharmaceuticals where he was responsible for CMC & Operations within the 
Autoimmune & Rare Diseases business unit. He also held similar roles at Questcor 
Pharmaceuticals, Cerecor Pharmaceuticals, Alba Therapeutics, Shire Pharmaceuticals and 
Guilford Pharmaceuticals. Dr. Ginski holds a B.S. in Biologics Sciences and a Ph.D. in 
Pharmaceutical Sciences from the University of Maryland. 
 
BOARD OF DIRECTOR PROPERTIES 
The board is made up of 8 members of which 1 is female and 7 are male. Of ANI Pharmaceutical 
has an average tenure of 6 years for its directors. The table below lists the directors: 
 
NAME TITLE COMPENSATION 
Robert E Brown 
Chairman of the Board and Chair of the Nominating 
and Corporate Governance Committee 
USD 273,573 
Thomas Haughey 
Director, Chair of the Audit and Finance 
Committee, and Member of the Compensation 
Committee 
USD 252,569 
Fred Holubow Director USD 27,226 
Tracy L. 
Marshbanks 
Director USD 35,748 
David Nash  
Director, Member of the Audit and Finance 
Committee, and Member of the Nominating and 
Corporate Governance Committee 
USD 243,994 
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Thomas A. Penn  
Director, Chair of the Compensation Committee, 
and Member of the Nominating and Corporate 
Governance Committee 
USD 205,264 
Daniel Raynor Director USD 33,854 
Patrick Walsh Director USD 245,709 
Arthur S Przybyl 




As of October 4, 2019, ANI Pharmaceuticals, Inc. had an ISS Governance Quality Score of 4. 
The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 1; and Compensation: 8. Its ISS 
Corporate governance scores is 1, relative to index or region. A decile score of 1 indicates lower 
governance risk, while a 10 indicates higher governance risk. 
 
ACCOUNTING QUALITY AND POLICIES 
EisnerAmper LLP has been the auditor of ANI’s consolidated financial statements since 2013. 
They are one of the largest full-service advisory and accounting firms in the US. The firm has 
received tht “Best of Accounting” Award for Client Service Excellence 3 times in a row now and 
have 18 offices, of which 5 are abroad. They are headquartered in New York.  
ANI’s latest 10K is for the period ended December 31, 2018 and the audit opinion given by its 
independent registered accounting firm, EisnerAmper LLP, was an unqualified opinion, 
concluding that the financial statements, taken as a whole, are presented fairly, in all material 
respects, in conformity with the applicable financial reporting framework. (AS 3101 Paragraph 
2) 
The consolidated financial statements for ANI are prepared in accordance with accounting 
principles generally accepted in the United States of America (“U.S. GAAP”). The functional 
currency for its subsidiary in Canada is the US dollars (USD). In the area of accounts receivable, 
credit is extended to customers on an unsecured basis and the allowance method used to provide 
for doubtful accounts is based on the evaluation of the collectability of accounts receivable, 
whereby allowance for doubtful accounts equal the estimated uncollectible amounts.  
Property, plant and equipment are recorded at cost, expenditures for repairs and maintenance are 
charged to expense as incurred and depreciation is recorded on a straight-line basis over 
estimated useful lives of 20-40 years for buildings and improvements, and 1-10 years for 
machinery, furniture and equipment.  
For Revenue recognition, the modified retrospective method is used. The process followed using 
this method is firstly, identification of the contract, or contracts, with a customer then 
identification of the performance obligations in the contract; determination of the transaction 
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price, including the identification and estimation of variable consideration; allocation of the 
transaction price to the performance obligations in the contract; and then recognition of revenue 
when we satisfy a performance obligation. 
For the year 2018, the quality of earnings ratio for ANI was 4.33 and the average for the five 
year period analyzed (2014-2018) is 2.77. These ratios indicate that ANI’s operating cash flow 




Below is a breakdown of the top 10 shareholders of ANI Pharmaceuticals Inc. (NMS: ANIP) stock 
as of 09/30/2019.  ANI Pharmaceuticals has 231 institutional holders, holding 10,591,900 shares, 
which make up 81.51 percent of the total shares outstanding. 









BLACKROCK INC. 6/30/2019 1,429,732 117,524 9.7566% 
VANGUARD GROUP INC 6/30/2019 564,317 46,387 3.8509% 
MANGROVE PARTNERS 6/30/2019 549,401 45,161 3.7492% 
DIMENSIONAL FUND ADVISORS INC 6/30/2019 537,427 44,175 3.6674% 
NOMURA HOLDINGS INC 6/30/2019 375,449 31,071 2.5621% 
DEUTSCHE BANK AG 6/30/2019 317,163 26,069 2.1643% 
FIRST MANHATTAN CO 6/30/2019 294,852 24,236 2.0121% 
STATE STREET CORP 6/30/2019 288,765 23,736 1.9706% 
RENAISSANCE TECHNOLOGIES LLC 6/30/2019 288,100 23,682 1.9660% 
INVESTMENT COUNSELORS OF 
MARYLAND LLC 
6/30/2019 279,979 23,014 1.9106% 
*Source: Mergent Online 
Total inside shareholders are 31, which include total direct shares of 4,137,447. The percentage of 
the shares held by the six largest insider shareholder as at 11/1/2019 is: 
Name % of insider shares held 
Brown Robert Jr 55.14% 
Morgensten Victor A 11.01% 
Przbyl Arthur 5.62% 
Cho Micheal 5.44% 
Perceptive Advisors LLC 5.44% 
Sherwin Stephen A 2.10% 
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25 people < 2% 15.26% 
  *Source: Mergent Online 
The detailed insider trading in the year 2019 is in the table below: 
  Trade Date   Insider Name Trade Type     Shares   
8/20/2019 Brown Robert E. Jr  Sale 5,512 
8/19/2019 Brown Robert E. Jr  Sale 2,067 
8/16/2019 Brown Robert E. Jr  Sale 26,349 
8/15/2019 Brown Robert E. Jr  Sale 9,315 
8/14/2019 Brown Robert E. Jr  Sale 26,360 
8/13/2019 Brown Robert E. Jr  Sale 20,821 
8/12/2019 Brown Robert E. Jr  Sale 21,016 
8/9/2019 Brown Robert E. Jr  Sale 19,860 
5/24/2019 Nash David  Buy 1,445 
5/17/2019 Marken James G. (SVP Ops & Prod Dev) Sale 8,907 
5/16/2019 Brown Robert E. Jr  Option Ex 2,209 
5/15/2019 Haughey Thomas  Buy 2,500 
5/14/2019 Marken James G. (SVP Ops & Prod Dev) Sale 4,917 
5/13/2019 Schrepfer Robert W (SVP - New Bus 
Dev & Spec Sales) 
Sale 2,409 
3/19/2019 Przybyl Arthur (President and CEO) Sale 2,823 
3/18/2019 Przybyl Arthur (President and CEO) Sale 24,802 
3/13/2019 Schrepfer Robert W (SVP - New Bus 
Dev & Spec Sales) 
Sale 4,651 
3/13/2019 Schrepfer Robert W (SVP - New Bus 
Dev & Spec Sales) 
Option Ex 4,651 
3/12/2019 Schrepfer Robert W (SVP - New Bus 
Dev & Spec Sales) 
Sale 7,145 
3/12/2019 Schrepfer Robert W (SVP - New Bus 
Dev & Spec Sales) 
Option Ex 7,145 
*Source: Insider Monitor 
 
INDUSTRY ANALYSIS 
ANI Pharmaceuticals operates under the NASDAQ exchange in the Pharmaceutical preparations 
industry with SIC code 2834 and Pharmaceutical Preparation Manufacturing Industry with NAICS 
code 325412. There are 2,488 companies in this industry in the USA with an estimated 
employment of 132,663 people.  
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Industry Description: The industry primarily manufactures, fabricates or process as drugs in 
preparation for human or veterinary use (e.g. tablets, capsules, ointments, solutions, etc.). Products 
of this industry consist of two important lines of pharmaceutical preparations: (1) those promoted 
primarily to the dental, medical, or veterinary professions and (2) those promoted primarily to the 
public. 
Industry classification: The Pharmaceutical preparations industry can be classified as a mature 
industry demonstrated by its expected diminishing revenue growth (from only specific therapeutic 
classes), a reduction of the workforce, and consolidation of operations. I forecast tis to experience 
more growth despite its challenges with the aging population and greater prevalence of chronic 
diseases. In 2017, U.S. pharmacy and drug store sales amounted to about USD 276.92 billion. In 
2019, the industry is expected to generate USD 844 billion in prescription drug revenue worldwide. 
Revenues are expected to reach nearly 1.2 trillion U.S. dollars by 2024. (Matej Mikulic, 2019) 
Current and expected degree of competition 
Rivalry among existing enterprises: The Pharmaceutical preparations industry is one of the most 
competitive industries in the world. With its large size, strict government regulations, the recent 
trend of mergers and acquisitions of small players by the big industries, the technological 
advancement and the constant pressure to innovate, it is safe to say that rivalry among existing 
enterprises is high. 
Threats of new entries: It is quite expensive to establish a pharmaceutical company (manufacturing 
set up, research and development, marketing sales and distribution) and it requires a long process 
of getting approval from the regulators. In addition, mistakes can be very costly, leading to subpar 
return on investments. As a result, there is a low threat from new entrants.  
Threats from product substitutes: Generic pharmaceutical products, alternative treatments (e.g. 
yoga, meditation, etc.), herbal treatments, and a healthier lifestyle (balanced diet and exercising) 
are some of the available substitutes for the pharmaceutical preparations industry.  
Bargaining power of parties involved 
Bargaining power of suppliers: Since the drugs are manufactured in house, the U.S pharmaceutical 
industry only needs to get raw materials and packaging materials from suppliers. Hence, there is 
no room for bargaining or trying to influence the market price. As a result, the bargaining power 
of suppliers is low. 
Bargaining power of clients: After a new drug is produced, the manufacturer gets a patent for 20 
years and after this time period, generic production begins and prices become more flexible, giving 




Political/Legal: The Federal government makes the rules and regulations that control the 
manufacturing of drugs and medicines. With the imposition of an additional USD 84.8 billion in 
taxes and discounts for Medicaid and Medicare patients in exchange for limiting bargaining to 
reduce drug prices, companies operating in the pharmaceutical industry either lose millions of 
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dollars by complying or risk paying other imposed prices to meet the needs of the customers 
covered under Medicare and Medicaid (Minimalist/Pharmacist, 2018) 
Economy: This include factors like interest rates, taxation changes, economic growth, inflation, 
and exchange rates. The growth of the Pharmaceutical industries aligns greatly with GDP growth. 
The unlimited demand for health care is confronted with limited resources for its funding. If a 
country’s GDP is too low to fund Research and Development, the Pharmaceutical industry will 
experience stagnancy and slowly decline. In addition, international trade with emerging 
pharmaceutical companies that provide low-cost, brand name pharmaceutical drugs to the US 
market impact competition. 
Technology: To develop a drug in this industry, it takes an average of USD 1.2 billion and an 
average time of 10 years. This limits the ability of many companies to develop new drugs or 
upgrade technology frequently. With the limit in technological advancement, and in addition to 
the high cost of drug development, fewer and fewer blockbuster drugs are being produced. 
Socio-cultural: The U.S and some other countries are currently looking after aging populations 
who have a high demand for more prescription drugs due to a greater prevalence of chronic 
ailments. One major social issue is the perception of cheaper generic drugs as adequate alternatives 
to more expensive brand name drugs. “According to Kaiser Family Foundation, consumers with 
Medicare Part D coverage have been utilizing generic drugs as these drugs are typically covered” 
(Minimalist/Pharmacist, 2018) 
Demographics: This refers to population, age, geographic, ethnic and income distribution. 
Demographic and changes greatly affects the development of this industry, and is a factor of 
demand for pharmaceutical products. The US Department of Health and Human Services reports 
that at least half of all Americans take a minimum of one prescription drug, with one in six taking 
three or more, excluding the frequent use of over-the-counter medications for easing a headache, 
such as aspirin, ibuprofen, etc. (Harding, 2013) 
Global: Deteriorating economic conditions, lack of raw materials, growing energy prices, growing 
environmental pollution and the fact that national and international regulations set increasingly 
strict standards are some of the factors affecting the Pharmaceutical industry on a global level. 
(Veselin Dickov, 2011) 
 
PEER ANALYSIS 
Listed below are some of ANI Pharmaceuticals Inc.’s main competitors. Each of these companies 
operate primarily in SIC Code 2834 (Pharmaceutical preparations) and NAICS Code 325412 
(Pharmaceutical Preparation Manufacturing). Their market caps are in close range and they are all 
located in the United States. 
Amphastar Pharmaceuticals Inc. is a specialty pharmaceutical company that deals primarily with 
the development, manufacturing and marketing of generic and proprietary injectable and 
inhalation products. Amphastar has two reportable segments, which are finished pharmaceutical 
products and active pharmaceutical ingredients (API) products. Their products include Enoxaparin 
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sodium injection, Cortrosyn, Amphadase, etc. Mary Luo is the CEO and the company has 2,078 
employees. It was incorporated in February 1996.  
Amneal Pharmaceuticals Inc is a pharmaceutical company that develops, manufactures, markets 
and distributes pharmaceutical products in a variety of dosage forms and therapeutic categories. It 
has two business segments namely Generics, and Specialty with a focus on products addressing 
central nervous system disorders, including migraine and Parkinson's disease. It was incorporated 
April 1993 in Florida, USA. The CEOs are Robert Stewart and Paul Bisaro and the company has 
approximately 6,000 employees. 
NGM Biopharmaceuticals Inc is a clinical stage biopharmaceutical company focused on 
developing novel therapeutics based on scientific understanding of key biological pathways 
underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. It is headquartered in South 
San Francisco, CA. The CEO is Dr. David J. Woodhouse and it has 164 full time employees. The 
company has research collaboration, product development, and license agreements with Merck 
Sharp & Dohme Corp., Medimmune Limited, and JDRF International. NGM Biopharmaceuticals, 
Inc. was incorporated in 2007. 
 




















ANIP 215.07 949.38 54.27 12.52 54.19% 6.29% 8.91% 
Amphastar 
Pharmaceuticals Inc 
AMPH 324.07 924 17.85 47.3 35.44% 0.22% 12.78% 
Amneal 
Pharmaceuticals Inc 




NGM 118.83 886 N/A -7.84 24.06% -2.85% -3.59% 
Source: Yahoo Finance 
These companies were chosen because they trade in the pharmaceutical preparations industry 
along with ANI Pharmaceuticals (SIC 2834) and have similar market capitalization of about 
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HISTORICAL FINANCIAL ANALYSIS 
As I mentioned earlier in the peer analysis, Amphastar Pharmaceuticals Inc. is one of the major 
competitors of ANI Pharmaceuticals. ANI Pharmaceuticals’ sales growth has decreased over the 
last three years, from 68.5% in 2016 to 14.0% in 2018. On the other hand, Amphastar Inc. 
experienced a tremendous increase in sales growth in 2018, which was a major turnaround for 
them as they also experienced a major decline of about 19% in the previous years. However, 
there has been an increase in invested capital turnover for ANI over the last five years, showing 
efficiency in production of revenues through debt and equity. ANI’s operating working capital 
turnover has been increasing steadily over the course of the last five years, from 0.31 in 2014 to 
1.98 in 2018, doing better than its competitor’s fluctuating turnover ratios. This shows that 
ANI’s management has being quite diligent in ensuring that it is generating a higher dollar 
amount of sales for every dollar of the working capital used and shows they are running 
smoothly and have limited need for additional funding. 
 PRODUCTIVITY RATIOS    
  2014 2015 2016 2017 2018 
Sales Growth ANI - 36.40% 68.50% 37.50% 14.00% 
 Amphastar - 19.50% 1.41% -5.90% 22.70% 
Receivable Turnover ANI 3.24 3.48 2.8 3.01 3.11 
 Amphastar 9.21 7.57 9.53 6.67 5.65 
Operating working capital turnover ANI 0.31 0.42 1.86 1.86 1.98 
 Amphastar 1.4 1.75 1.77 1.49 1.63 
 
The current ratio of ANI Inc. dropped below 1 to 0.94 in 2018 from 3.56 in 2017, showing that 
its current liabilities outweighed its current assets. Meanwhile, Amphastar Inc., though showing 
more liquidity in that area than ANI, its current ratios seem to be too high (7.51 in 2017), 
implying that it is not efficiently using its current assets or short-term financing liabilities. 
Amphastar also showed relatively higher quick ratios than ANI. ANI’s quick ratios went from 
16.95 in 2015, to 2.53 in 2016, 2.54 in 2017 and 0.69 in 2016. Regarding the short-term 
investments over invested capital, ANI has had a constant 0.01 over the course of the last five 
years, while Amphastar has moved from 0.00 to 0.02 within the 5 years analyzed. In general, 
ANI seems to less liquid than Amphastar. 
 LIQUIDITY RATIOS     
  2014 2015 2016 2017 2018 
Current Ratio ANI 16.48 18.22 3.4 3.56 0.94 
 Amphastar 3.47 3.95 4.09 7.15 4.34 
Quick Ratio ANI 15.84 16.96 2.53 2.54 0.69 
 Amphastar 1.87 2.36 2.32 4.73 2.98 
Short-term investments over invested 
capital ANI 0.01 0.01 0.01 0.01 0.01 
 Amphastar 0.00 0.00 0.01 0.02 0.02 
 
ANI Pharmaceuticals (ANIP) MSUM Paseka School of Business November 1, 2019 
P a g e  13 | 19 
 
In the area of financial risk, the interest coverage ratio shows that ANI can efficiently cover its 
current interest payments with its available earnings as its accounting-based and cased-based 
ratios are 2.31 and 4.51 respectively. Amphastar’s interest coverage ratio is not as good as its 
accounting based ratio is in the negative 6.62. Both ANI and Amphastar have moderate debt to 
equity ratios (1.04 and 0.24 respectively as at 2018) which indicate low levels of risk. However, 
although both companies’ ratios seem to be increasing every year, ANI has more assets financed 
by debt than those financed by shareholders' funds and for Amphastar, the opposite is the case.  
 LEVERAGE RATIOS     
  2014 2015 2016 2017 2018 
Interest Coverage ratio (Accounting-based) ANI 31.91 2.98 1.76 2.36 2.31 
 Amphastar N/A 1.99 21.03 1.41 N/A 
Interest Coverage ratio (Cash-based) ANI 38.09 3.61 3.72 4.7 4.51 
 Amphastar N/A 1.27 37.18 N/A 4.53 
Total debt equity ANI 0.78 0.67 0.75 1.23 1.04 
 Amphastar 0.16 0.13 0.11 0.14 0.24 
*All ‘N/A’ represent negative numbers 
In the area of profitability, ANI has shown generally higher figures than Amphastar. Return on 
Assets (ROA) has been higher than Amphastar’s with about 2% in the last two years showing 
steady increase in the last three years, after the big drop from 12.20 percent to 6.77 percent in 
2016. ANI’s EBITDA margin has been sustainably higher than Amphastar’s by about 11% or 
more for the last 5 years, with ANI having 34.3 percent and Amphastar, 2.0 percent in 2018. The 
gross profit margin has been higher with about 15% over the last five years also, with ANI 
showing steady increase in the last three years. ANI’s ROIC was 6.25 percent in 2018 while 
Amphastar had a -2.41 percent. It is safe to conclude that ANI has shown more profitability over 
the years than its competitor. However, the ROIC is lower than the average cost of funding in 
some of the years. This is a sign that the company might not be earning enough to compensate 
investors in some of the years. 
 PROFITABILITY RATIOS    
  2014 2015 2016 2017 2018 
ROA ANI -4.96% 1.90% 3.96% -0.83% -1.79% 
 Amphastar 8.06% 12.20% 6.77% 7.27% 8.78% 
EBITDA ANI 42.70% 51.90% 33.00% 31.80% 34.30% 
 Amphastar -2.60% 1.80% 10.90% 3.80% 2.00% 
ROIC ANI - 9.07% 0.07% 0.65% 6.25% 
 Amphastar - -2.62% 2.86% -1.91% -2.41% 
Gross Profit Margin ANI 79.50% 83.40% 56.90% 54.80% 63.80% 
 Amphastar 30.10% 35.20% 45.60% 43.00% 41.20% 
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PROSPECTIVE FINANCIAL ANALYSIS 
I projected sales to grow at 13% in 2019, 12% in 2020, 9% in 2021 and 6% in 2022, dropping 
steadily until it grows at a rate of about 5% perpetually, in line with the company’s estimate of 
5.10% growth. My 2019-2021 projections are quite optimistic in light of the pricing pressure and 
underperformance in the US generics market; however, with ANI’s launch of Ranitidine, its 
approval for the commercialization of Vancocin oral solution and its trend of exceeding 
estimates and surpassing both the market and competitors, I see it as a fair estimate of ANI’s 
sales growth. 
I project COGS as a percentage of sales to decrease steadily over the next 5 years starting at 30% 
in 2019 and dropping to 25% by 2023. ANI has learned to decrease its inventory cost over the 
years, purchasing a bulk of its inventory from one or two suppliers. In addition, increased royalty 
revenues, the change in product mix towards higher-margin brand products and lower sales of 
products subject to profit-sharing arrangements will help in reduction of COGS as a percentage 
of sales.  
I project operating capital ratios to be constant over the years, as ANI has not disclosed any plans 
to carry out capital projects that can distort their usual trend. Finally, I estimate the WACC to be 
10.59 percent and the ROIC to be 16.2 percent. To arrive at my WACC, I set the target percent 
financed with long-term debt to be at 15 percent, the target percent financed with short term debt 
to be at 17.55 percent and the cost of equity to be at 13.20 percent (beta = 1.7, risk-free rate = 3 
percent and market risk premium = 6 percent). The marginal tax rate of 21% was used and the 
cost of long term debt was calculated to be 6%. The after tax cost of long-term debt and an after 
tax cost of short-term debt of were 4.74%. 
 
VALUATION AND INVESTMENT DECISION 
I used a corporate valuation model based on discounting expected Free Cash Flows at the 
Weighted Average Cost of Capital. I derive a stock price of USD 61.59 per share by November 
1, 2019. I used Mergent Online to download financial statements for the latest five-year period. 
The most recent published financial information for ANI Pharmaceuticals is for the last quarter 
ended, September 30th, 2019. 
In addition, I complement my fundamental analysis with a relative valuation using Amphastar 
Pharmaceuticals, ANI’s competitor, to estimate the price per share for ANI’s stock. According to 
the multiples Price/Sales, Price/Earnings, and Market/Book, ANI’s stock is overvalued and 
considered a sell. ANI Pharmaceuticals has experienced notable instability in its stock prices in 
the past two years. Its stock went from USD 43.86 as at 7/31/17, to USD 70.67 on 11/27/2017, 
four months later. As at 12/17/2018, it was at USD 41.17 and then it went up to USD 84.26 on 
7/22/2019, and since then, it been dropping. Although, ANI’s stock price is undervalued 
according to the multiple EV/EBITDA, I do not give too much credit to this ratio given the 
current differences in the margins of these two companies.  
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Multiples AMPH Value ANIP Value PPS Valuation Investment decision 
Price/Sales  2.72 16.67 45.3424 overvalued Sell 
Price/Earnings  29.29 1.45 42.4705 overvalued Sell 
EV/EBITDA  47.69 69101 257.3958 undervalued Buy 
Market/Book 2.31 17.48 40.3788 overvalued Sell 
 
In summary, I estimate the stock price for ANI’s stock to be USD 61.59 at 11/1/2019, which is 
lower than the current market price of USD 78.48 (a difference of USD 16.89). Therefore, I 
recommend a SELL on the stock. 
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ANI Pharmaceuticals Inc (NMS: ANIP)
In thousands of USD
Income Statement 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023
Sales 128622.0 176842.0 201576.0 227780.9 255114.6 278074.9 294759.4 309497.4
Costs of goods sold (COGS) 55465.0 79935.0 73024.0 68334.3 69646.3 72299.5 74574.1 77374.3
Sales, general and administrative expense (SGA) 30735.0 40650.0 59451.0 59678.6 66840.0 72855.6 77227.0 81088.3
Depreciation 22343.0 27928.0 33742.0 17349.4 19431.3 21180.1 22450.9 23573.5
Operating profit 20079.0 28329.0 35359.0 82418.6 99197.0 111739.7 120507.4 127461.2
Interest expense 11401.0 11980.0 15308.0 16516.0 27602.3 29812.6 31694.1 33186.9
Interest income 0.0 0.0 0.0 135.7 3323.0 4197.9 5478.9 7187.0
Nonoperating income (Expense) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Earnings before taxes (EBT) 8678.0 16349.0 20051.0 66038.4 74917.7 86124.9 94292.2 101461.3
Tax expense 4744.0 17425.0 4557.0 14990.7 17006.3 19550.4 21404.3 23031.7
Net income before extraordinary items 3934.0 (1076.0) 15494.0 51047.7 57911.4 66574.6 72887.9 78429.6
After-tax extraordinary income (Expense) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Net income (NI) 3934.0 (1076.0) 15494.0 51047.7 57911.4 66574.6 72887.9 78429.6
Dividends-- preferred 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Dividends-- common 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Additions to RE 3934.0 (1076.0) 15494.0 51047.7 57911.4 66574.6 72887.9 78429.6
Balance Sheet 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023
Assets
Cash 27365.0 31144.0 43008.0 44417.3 49747.3 54224.6 57478.1 60352.0
Inventory 26183.0 37727.0 40503.0 45784.0 51278.0 55893.1 59246.6 62209.0
Accounts receivable 45895.0 58788.0 64842.0 73345.4 82146.9 89540.1 94912.5 99658.2
Other short-term operating assets 0.0 1162.0 0.0 0.0 0.0 0.0 0.0 0.0
Short-term investments 3564.0 2784.0 4524.0 110768.3 139930.6 182631.5 239566.8 304449.6
Total current assets 103007.0 131605.0 152877.0 274314.9 323102.9 382289.3 451204.0 526668.7
Net plant, property, & equipment (PPE) 10998.0 20403.0 38090.0 43050.6 48216.7 52556.2 55709.5 58495.0
Other long-term operating assets 182632.0 236634.0 210205.0 271059.2 303586.4 330909.1 350763.7 368301.9
Long-term investments 0.0 829.0 1468.0 1662.8 1862.3 2029.9 2151.7 2259.3
Total assets 296637.0 389471.0 402640.0 590087.6 676768.2 767784.5 859829.0 955724.9
Liabilities and Equity
Accounts payable (AP) 3389.0 3630.0 8884.0 7289.0 8163.7 8898.4 9432.3 9903.9
Accruals 3325.0 1571.0 7440.0 5239.0 5867.6 6395.7 6779.5 7118.4
Other operating current liabilities 23603.0 28368.0 29982.0 33939.4 38012.1 41433.2 43919.1 46115.1
All short-term debt 0.0 3353.0 115719.0 165359.6 178601.1 189872.6 198815.7 207009.1
Total current liabilities 30317.0 36922.0 162025.0 211826.9 230644.5 246599.9 258946.6 270146.5
Long-term debt 120643.0 198154.0 67792.0 141333.0 152650.5 162284.3 169927.9 176930.8
Deferred taxes (26227.0) (22667.0) (27964.0) (15369.1) (17213.3) (18762.5) (19888.3) (20882.7)
Preferred stock 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Other long-term liabilities 2256.0 2306.0 3524.0 3986.2 4464.5 4866.3 5158.3 5416.2
Total liabilities 126989.0 214715.0 205377.0 341776.9 370546.2 394987.9 414144.5 431610.8
Par plus PIC Less treasury (and other adjustments) 137215.0 143399.0 150412.0 150412.0 150412.0 150412.0 150412.0 150412.0
Retained earnings (RE) 32433.0 31357.0 46851.0 97898.7 155810.0 222384.6 295272.5 373702.1
Total common equity 169648.0 174756.0 197263.0 248310.7 306222.0 372796.6 445684.5 524114.1
Total liabilities and equity 296637.0 389471.0 402640.0 590087.6 676768.2 767784.5 859829.0 955724.9
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ANI Pharmaceuticals Inc (NMS: ANIP)
In thousands of USD
Statement of Cash Flows 42735.0 43100.0 43465.0 43830.0 44196.0 44561.0 44926.0 45291.0
Operating Activities
Net income 3934.0 (1076.0) 15494.0 51047.7 57911.4 66574.6 72887.9 78429.6
Depreciation 22343.0 27928.0 33742.0 17349.4 19431.3 21180.1 22450.9 23573.5
Change in deferred tax (8911.0) 3560.0 (5297.0) 12594.9 (1844.3) (1549.2) (1125.8) (994.4)
Change in inventory (12796.0) (11544.0) (2776.0) (5281.0) (5494.1) (4615.0) (3353.6) (2962.3)
Change in accounts receivable (23963.0) (12893.0) (6054.0) (8503.4) (8801.5) (7393.2) (5372.4) (4745.6)
Change in other short-term operating assets 1127.0 (1162.0) 1162.0 0.0 0.0 0.0 0.0 0.0
Change in accounts payable 1323.0 241.0 5254.0 (1595.0) 874.7 734.7 533.9 471.6
Change in accruals 2708.0 (1754.0) 5869.0 (2201.0) 628.7 528.1 383.7 339.0
Change in other current liabilities 15718.0 4765.0 1614.0 3957.4 4072.7 3421.1 2486.0 2196.0
Net cash from operating activities 1483.0 8065.0 49008.0 67368.9 66778.9 78881.2 88890.7 96307.2
Investing Activities
Investment in PPE (26210.0) (37333.0) (51429.0) (22310.0) (24597.4) (25519.6) (25604.3) (26359.0)
Investment in other long-term oper. ass. (114397.0) (54002.0) 26429.0 (60854.2) (32527.1) (27322.8) (19854.5) (17538.2)
Net cash from investing activities (140607.0) (91335.0) (25000.0) (83164.2) (57124.5) (52842.4) (45458.9) (43897.1)
Financing Activities
Change in short-term investments (2111.0) 780.0 (1740.0) (106244.3) (29162.3) (42700.9) (56935.3) (64882.8)
Change in long-term investments 0.0 (829.0) (639.0) (194.8) (199.5) (167.6) (121.8) (107.6)
Change in short-term debt 0.0 3353.0 112366.0 49640.6 13241.6 11271.5 8943.1 8193.4
Change in long-term debt 7216.0 77511.0 (130362.0) 73541.0 11317.6 9633.7 7643.7 7002.9
Preferred dividends 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Change in preferred stock 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Change in other long-term liabilities 1068.0 50.0 1218.0 462.2 478.3 401.8 292.0 257.9
Change in common stock (Par + PIC) 5632.0 6184.0 7013.0 0.0 0.0 0.0 0.0 0.0
Common dividends 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
         Net cash from financing activities 11805.0 87049.0 (12144.0) 17204.6 (4324.4) (21561.5) (40178.4) (49536.2)
Net cash flow (127319.0) 3779.0 11864.0 1409.3 5330.1 4477.3 3253.5 2873.9
Starting cash 154684.0 27365.0 31144.0 43008.0 44417.3 49747.3 54224.6 57478.1
Ending cash 27365.0 31144.0 43008.0 44417.3 49747.3 54224.6 57478.1 60352.0
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ANI Pharmaceuticals Inc (NMS: ANIP)
In thousands of USD
Ratios 2018 2017 2016 2015 2014
Productivity Ratios
     Growth in sales 14.0% 37.5% 68.5% 36.4% #DIV/0!
     Receivables turnover 3.11 3.01 2.80 3.48 3.24
     Inventory turnover 4.98 4.69 4.91 5.70 7.44
     Operating working capital turnover 1.98 1.86 1.86 0.42 0.31
     Net fixed asset turnover 0.81 0.69 0.66 1.01 1.07
     Total asset turnover 0.50 0.45 0.43 0.28 0.23
     Invested capital turnover 0.58 0.50 0.49 0.30 0.24
Liquidity Ratios
     Current ratio 0.94 3.56 3.40 18.22 16.48
     Quick ratio 0.69 2.54 2.53 16.96 15.84
     Cash ratio 0.29 0.92 1.02 14.77 14.39
     Short-tern investments over invested capital 0.01 0.01 0.01 0.01 0.01
     Operating Cycle 190.75 199.21 204.54 168.91 161.83
     Cash Cycle 174.66 191.71 194.92 159.03 144.52
Financial Risk (Leverage) Ratios
     Total debt-to-equity ratio 1.04 1.23 0.75 0.67 0.78
     Total debt-to-equity ratio (excluding deferred taxes) 1.18 1.36 0.90 0.78 0.89
     Total financial debt-to-equity ratio 0.93 1.15 0.71 0.71 0.79
     Interest coverage ratio (accounting-based) 2.31 2.36 1.76 2.98 31.91
     Interest coverage ratio (cash-based) 4.51 4.70 3.72 3.61 38.09
     Total debt-to-assets ratio 0.51 0.55 0.43 0.40 0.44
     Total financial debt over total assets 0.46 0.52 0.41 0.42 0.45
     Long-term financial debt over invested capital 0.19 0.56 0.46 0.44 0.47
Profitability/Valuation Ratios
     Gross profit margin 63.8% 54.8% 56.9% 83.4% 79.5%
     EBITDA margin 34.3% 31.8% 33.0% 51.9% 42.7%
     Operating profit margin 17.5% 16.0% 15.6% 42.8% 35.7%
     NOPAT margin 10.9% 1.0% 0.1% 27.9% 25.4%
     Earnings before taxes margin 9.9% 9.2% 6.7% 28.5% 34.6%
     Net margin 7.7% -0.6% 3.1% 20.1% 51.4%
     Return on Assets 8.78% 7.27% 6.77% 12.20% 8.06%
     Net investment rate -8.84% 5280.49% 3567.06% 101.27% 1646.30%
     Dividend payout ratio 0.00% 0.00% 0.00% 0.00% 54.35%
     ROIC 6.25% 0.65% 0.07% 9.07% #DIV/0!
